Table 2.
—Clinical Characteristics of Patients With Scleroderma
| Characteristic | Absent, No. (%) | Present, No. (%) | Missing, No. (%) |
| Clinical data | |||
| Raynaud phenomenon | 0 (0) | 64 (100) | 0 (0) |
| Pitting nail | 9 (14) | 25 (39) | 30 (47) |
| Skin sclerosis | 33 (52) | 29 (45) | 2 (3) |
| Calcinosis | 50 (78) | 10 (16) | 4 (6) |
| Sclerodactyly | 10 (16) | 53 (83) | 1 (2) |
| Telangiectasia | 15 (23) | 49 (77) | 0 (0) |
| Digital ulcer | 31 (48) | 31 (48) | 2 (3) |
| Heartburn | 19 (30) | 45 (70) | 0 (0) |
| Dysphagia | 32 (50) | 31 (48) | 1 (2) |
| Dysmotility | 35 (55) | 20 (31) | 9 (14) |
| Diarrhea | 44 (69) | 16 (25) | 4 (6) |
| Myositis | 52 (81) | 8 (13) | 4 (6) |
| Hypertension | 29 (45) | 35 (55) | 0 (0) |
| Laboratory data | |||
| ANA | 2 (3) | 58 (91) | 4 (6) |
| Anti-Scl-70 | 34 (53) | 5 (8) | 25 (39) |
| ACA | 26 (41) | 21 (33) | 17 (26) |
| Organ Involvement | |||
| CKD | 37 (58) | 21 (33) | 6 (9) |
| CHF, systolic | 48 (75) | 5 (8) | 11 (17) |
| CHF, diastolic | 24 (38) | 22 (34) | 18 (28) |
| PAH | 34 (53) | 14 (22) | 16 (25) |
| ILD | 45 (70) | 19 (30) | 0 (0) |
ACA = anticentromere antibody; ANA = antinuclear antibody; anti-Scl-70 = antitopoisomerase I; CHF = congestive heart failure; CKD = chronic kidney disease; ILD = interstitial lung disease; PAH = pulmonary arterial hypertension.